Spinal stenosis of lumbar region

Coreline Soft announces first China partnership South Korean medical AI company Coreline Soft has entered into its first partnership in China. It signed a memorandum of understanding with Suhai Information Technology, which reportedly runs a network of medical institutions in China. Coreline Soft will tap into this network to collect clinical data, which will help tailor its AI software offerings to local hospitals. Besides promoting AI adoption as part of early chronic disease diagnosis, Coreline Soft and Suhai will also collaborate to research and develop new AI-based solutions, including a CDSS platform. Additionally, they will work on several government-led health research projects targeting chronic obstructive pulmonary disease and interstitial lung disease. The Korean company has identified China, whose medical AI market is worth around 38.8 billion yuan ($5 billion), as one of the three key Asian markets it targets for expansion. It has already established its presence in both Taiwan and Japan. Cureskin launches hair analysis AI feature Dermatology AI company Cureskin from India has integrated a new AI feature on its mobile application that analyses hairlines and detects male pattern baldness. According to a media release, its hair analysis model was trained using "thousands of clinical images" to identify early signs of hair recession, thinning, and density reduction. The Cureskin app also utilises advanced image processing to analyse photos of a user's hairline. Last year, Cureskin raised $20 million in Series B funding to enhance its AI capabilities. Korean researchers develop lumbar stenosis AI Researchers from Seoul National University Hospital (SNUH) have created an AI model for diagnosing lumbar spinal stenosis on X-ray images. Based on a media release, the team utilised existing AI models to train their model with X-ray images of lumbar stenosis taken in neutral, flexed, and extended postures, which they said reduces false-positive and negative errors. In a study, their model demonstrated 91.4% accuracy in detecting the condition using a set of X-ray images from 5,000 SNUH patients from 2005 to 2017. Lumbar stenosis is characterised by persistent back pain due to the spinal canal narrowing and compressing the nerves connecting the lower body. The SNUH research team is now working to integrate the AI into a commercial application. Remidio integrates risk assessment in mobile diabetic retinopathy screening Remidio, developer of mobile solutions for diabetic retinopathy (DR) screening in India, has recently collaborated with Iceland-based RetinaRisk for technology integration. They integrated Remidio's automated DR detection and baseline severity grading capabilities and RetinaRisk's risk prediction algorithm with real-time retinal grading into mobile DR point-of-care screening. A press release noted that RetinaRisk's algorithm has shown 85% accuracy in predicting DR and demonstrated potential to reduce screening frequency by 56%. The partners will pilot the integrated solution in specific populations with high diabetes prevalence in India.

FRIDAY, Feb. 21, 2025 -- There is some evidence for epidural steroid injections (ESIs) reducing pain and disability in cervical and lumbar radiculopathies and possibly in lumbar spinal stenosis, according to a study published online Feb. 12 in Neurology . Carmel Armon, M.D., from Loma Linda University School of Medicine in California, and colleagues conducted a systematic review to evaluate the use of ESIs in cervical and lumbar spinal stenosis and radiculopathies. Due to the variability in efficacy measures, differences based on any measure of success were reported as the success rate difference (SRD). Ninety randomized controlled trials met the inclusion criteria. The researchers found that ESIs probably reduced short-term pain (SRD, −24.0 percent; number needed to treat [NNT], 4) and disability (SRD, −16.0 percent; NNT, 6) and possibly reduced long-term disability (SRD, −11.1 percent; NNT, 9) in cervical and lumbar radiculopathies. The evidence was insufficient to determine whether ESIs reduced long-term pain in radiculopathies. ESIs possibly reduced short-term (SRD, −26.2 percent; NNT, 4) and long-term (SRD, −11.8 percent; NNT, 8) disability in lumbar spinal stenosis, but there was no reduction in short-term pain; insufficient evidence was seen for determining whether ESIs reduced long-term pain. The evidence was insufficient for determining the effectiveness of ESIs in cervical spinal stenosis. "The systematic review found evidence that ESIs are probably effective in reducing short-term pain and disability caused by radiculopathy and possibly effective in reducing short-term disability, but not pain, in lumbar spinal stenosis," the authors write. Several authors disclosed ties to industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that it has completed the acquisition of Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis. “The acquisition of Vertos Medical enhances our unique, non-surgical solutions for interventionalists addressing chronic lower back pain, while broadening our presence in ambulatory surgery centers,” said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. “We look forward to enabling physicians with the minimally invasive mild ® procedure so patients can reclaim their quality of life.” The addition of Vertos Medical’s differentiated portfolio will strengthen Stryker’s impact in interventional solutions to address chronic pain. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at . Media contact Beth Sizemore Sr. Director, Strategic Communications beth.sizemore@stryker.com